Osso e Ossos; Técnicas de Transferência de Genes; Terapia Genética; Medicina Regenerativa; Engenharia Tecidual; Animais; Vetores Genéticos; Humanos; Camundongos; Vírus

AAV; ASCs; AcMNPV; AdBMP2; Autographa californica multiple nucleopolyhedrovirus; BMP; BMP-2; BMSCs; Bone; CT; CXC chemokine receptor-4; CXCR4; Cox-2; DBM; EC; ECM; EPCs; FGF-2; FLP; Frt; GAM; Gene delivery approach; Gene therapy; HIF-1α; IFN-γ; IL-6; LLP2A; MDSCs; MSCs; NZW; New Zealand White; PDGF; PET; RANKL; Regenerative medicine; SATB2; Sca-1; Stem cell; TGF-ß; TLR-3; TNF-α; TRAP; Tissue engineering; VEGF; Viral vectors; adeno-associated virus; adenovirus expressing BMP-2; adipose-derived stem cells; bone marrow-derived mesenchymal stem cells; bone morphogenetic protein; bone morphogenetic protein 2; computed tomography; cycloxygenase-2; demineralized bone matrix; endothelial cells; endothelial progenitor cells; extracellular matrix; fibroblast growth factor-2; flippase; flippase recognition target; gene activated matrix; hypoxia-inducible factor 1α; i.v.; iPSCs; induced pluripotent stem cells; interferon-γ; interleukin 6; intravenous; mesenchymal stem cells; miRNA; microRNA; muscle-derived stem cells; peptidomimetic ligand; platelet-derived growth factor; positron emission tomography; receptor activator of nuclear factor κB ligand; siRNA; small interfering RNA; special AT-rich sequence-binding protein 2; stem cell antigen-1; tartrate-resistant acid phosphatase; toll-like receptor 3; transforming growth factor ß; tumor necrosis factor-α; vascular endothelial growth factor